Current status and future prospects for satraplatin, an oral platinum analogue
about
Redox activation of metal-based prodrugs as a strategy for drug deliveryThe Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) ProdrugsRuthenium anticancer compounds: myths and realities of the emerging metal-based drugs.Bromines on N-allyl position of cationic porphyrins affect both radio- and photosensitizing properties.Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed.Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate.Metal complexes as potential modulators of inflammatory and autoimmune responses.The new platinum-based anticancer agent LA-12 induces retinol binding protein 4 in vivoNanocarriers for delivery of platinum anticancer drugs.Comparative in vitro and in vivo pharmacological investigation of platinum(IV) complexes as novel anticancer drug candidates for oral application.Tumor microenvironment in focus: LA-ICP-MS bioimaging of a preclinical tumor model upon treatment with platinum(IV)-based anticancer agents.Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study.Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma.PCPH/ENTPD5 expression confers to prostate cancer cells resistance against cisplatin-induced apoptosis through protein kinase Calpha-mediated Bcl-2 stabilization.Novel metals and metal complexes as platforms for cancer therapyCurrent applications and future potential for bioinorganic chemistry in the development of anticancer drugs.Satraplatin for the therapy of castration-resistant prostate cancer.Clinical and pharmacokinetic evaluation of satraplatin.Targeting and delivery of platinum-based anticancer drugs.The hurdle of antiandrogen drug resistance: drug design strategies.Target-selective delivery and activation of platinum-based anticancer agents.Current State of Metal-Based Drugs for the Efficient Therapy of Lung Cancers and Lung Metastases.Antileukemic action of novel diamine Pt(II) halogenido complexes: Comparison of the representative novel Pt(II) with corresponding Pt(IV) complex.RGD-mediated delivery of small-molecule drugs.Behavior of platinum(iv) complexes in models of tumor hypoxia: cytotoxicity, compound distribution and accumulation.Oral delivery of a platinum anticancer drug using lipid assisted polymeric nanoparticles.Advances in oral delivery of anti-cancer prodrugs.The ligation of aspirin to cisplatin demonstrates significant synergistic effects on tumor cells.Platinum-(IV)-derivative satraplatin induced G2/M cell cycle perturbation via p53-p21(waf1/cip1)-independent pathway in human colorectal cancer cells.Higher anti-tumour efficacy of platinum(IV) complex LA-12 is associated with its ability to bypass M-phase entry block induced in oxaliplatin-treated human colon cancer cells.Maleimide-functionalised platinum(IV) complexes as a synthetic platform for targeted drug delivery.Unsymmetric mono- and dinuclear platinum(IV) complexes featuring an ethylene glycol moiety: synthesis, characterization, and biological activity.Mono-carboxylated diaminedichloridoplatinum(IV) complexes--selective synthesis, characterization, and cytotoxicity.Evaluation of satraplatin in dogs with spontaneously occurring malignant tumors.Mitochondrial mode of action of a thymidine-based cisplatin analogue breaks resistance in cancer cells.Reduction of ormaplatin and cis-diamminetetrachloroplatinum(iv) by ascorbic acid and dominant thiols in human plasma: kinetic and mechanistic analyses.The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin.Synthesis and in vitro anticancer activity of octahedral platinum(IV) complexes with cyclohexyl-functionalized ethylenediamine-N,N'-diacetate-type ligands.Thiolated chitosan-modified PLA-PCL-TPGS nanoparticles for oral chemotherapy of lung cancer.Ruthenium- and osmium-arene complexes of 8-substituted indolo[3,2-c]quinolines: Synthesis, X-ray diffraction structures, spectroscopic properties, and antiproliferative activity.
P2860
Q27025736-1E8F99E6-A1C1-40C8-BC52-2DF2C8DF34B7Q28066801-224A1896-4420-4AB4-A678-E9FDA01E6E04Q30403317-4138EBA6-0F90-48D1-BC40-2B14C6A31E55Q33413106-8608B897-DC7E-4FF1-9731-71A2B583F41AQ33414629-21782F2A-AF0E-441C-8B0E-E9CA57FB171BQ33564338-CFE29082-B748-466C-8591-AF018BED9872Q33805225-A693FCFA-2573-4E13-9AD6-27E1394E8E84Q34062814-CDCAE5D0-CB53-46ED-BAD5-771D5525F60BQ34338695-FDE1C65C-D9A1-4A26-8038-EFB8F3762819Q35154374-A671D38F-2400-472B-A91E-88444DF936B5Q35598162-3191D94A-3008-4F06-846E-B958E0AD53D6Q35932794-0C98B850-6369-42C3-A558-B8876CE3C183Q36159154-953E641C-2737-421D-94B9-346329E237F9Q37038041-C0D344F8-97E1-40F8-92DA-28FEFA48A197Q37137649-C7DA8871-89CF-4A3F-ABBA-81C2FABBB6A4Q37603642-A8947210-0DC1-4327-AA25-383BBB432BABQ37605845-584CB5E4-C39E-4138-B068-E8A325D823A6Q37958009-EC9C12B6-1E2C-4AA9-BEE0-9FDF75D59649Q38050063-32A1D93C-8DA2-455B-B2D8-FFF83E4326F5Q38160927-46323E50-AD4B-4EC0-80C7-F9AB2DD2F638Q38523600-B7A5B855-6016-4AEE-8CEF-7879AAA01618Q38669290-2DC91DC1-0C70-49BA-8131-8D141CF573C4Q38720587-A8360F65-3B99-4CDD-B013-3B04A63ABA68Q38732486-EB3FAF48-3BB0-4E59-9430-4DC4EDF0D72DQ38795441-03874BB6-FA12-474F-AFAF-FD690FD3108BQ38826655-1871ECD8-9569-4EBB-8EDD-44678F15BDF0Q38862820-7B071AC0-5ADD-4385-8B95-0CE251CBB83BQ39000659-C0720B92-EC4E-4ABE-8691-0E24C3A66994Q39018004-58624AB5-6604-4F59-A27E-13A909ABB300Q39080724-ABF98AF8-CEAC-4331-90DA-06CED2A48256Q39196999-D5A76C4D-8A70-4E72-A181-82B150C50954Q39235908-C1D11362-3571-42A4-9CE3-7BFF0B117476Q39509386-8DCA1C0D-852D-49B2-B9D4-1FA5B242D58DQ39544355-10A161D0-348E-4844-968F-AE49F3B46DBBQ39638924-B6D938BF-6C51-429A-B0F6-651C6FDA13E9Q39666981-2FAE1D7A-55F7-4122-998D-30123DCD556BQ39692780-9A15C5C7-6569-4F7B-897E-0F2D5E3ACD8EQ39712439-D0D9A464-FB5B-486E-90D3-4EFDF7129E74Q41071914-8B78B82E-1133-4752-B271-451CC6D2FA2EQ41642755-1EA9A498-70A4-452C-B1E5-C0C04061BF14
P2860
Current status and future prospects for satraplatin, an oral platinum analogue
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Current status and future prospects for satraplatin, an oral platinum analogue
@ast
Current status and future prospects for satraplatin, an oral platinum analogue
@en
Current status and future prospects for satraplatin, an oral platinum analogue
@nl
type
label
Current status and future prospects for satraplatin, an oral platinum analogue
@ast
Current status and future prospects for satraplatin, an oral platinum analogue
@en
Current status and future prospects for satraplatin, an oral platinum analogue
@nl
prefLabel
Current status and future prospects for satraplatin, an oral platinum analogue
@ast
Current status and future prospects for satraplatin, an oral platinum analogue
@en
Current status and future prospects for satraplatin, an oral platinum analogue
@nl
P2093
P1476
Current status and future prospects for satraplatin, an oral platinum analogue
@en
P2093
P304
P356
10.1158/1078-0432.CCR-07-2176
P407
P577
2008-03-15T00:00:00Z